Our Services and Platform Technologies
RxCelerate offers world class platform technologies and services from early in silico discovery through to preclinical studies.
Our Services
Our highly talented teams of scientists can deliver specific services as well as running complete drug discovery projects, with teams from different departments working closely together to provide a fully integrated approach.
IN SILICO DESIGN
ANTIBODY DISCOVERY
Isolation of fully human antibodies using our ‘Galaxy’ platform. Immune library generation & humanisation expertise.
Chemistry
Generation of high-quality hit material, development candidates, and active pharmaceutical ingredients as quickly and cost-effectively as possible.
IN VITRO
In vitro assay design and development including cell-based and plate-based assays, molecular and biochemical assays and ICC.
DROSOPHILA
Design and development of assays using Drosophila melanogaster, enabling drug screening in a whole organism with a quick turnaround.
Preclinical
Complete in vivo and histology services covering a wide range of disease areas and therapeutic approaches.
Proteomics
Using ProQuant®, our proteomics platform, for performing LC-MS/MS bottom-up proteomics on a wide range of biological samples.
Project Management
Client-focused project management, driven by best practices, with experienced project managers that can input at all stages from concept to clinic.
Our Platform Technologies
Our proprietary technologies give a unique advantage to your drug discovery project.
Antibody Discovery Platform
Proprietary human antibody discovery platform, which combines the biology of B-cell selection and in vitro methodologies to maximise diversity and find high quality leads.
Dynamic Chemical Space
First commercially available dynamic chemical space allowing in silico screening of billions of novel small molecules against a target in a matter of weeks.
Proteomics Platform
Unique proteomics platform offering quantitative precision and unbiased analysis of proteins and their modifications in simple and complex matrices.
RxCelerate offers a unique business model catering to both small molecules and biologics. We work with you to drive your asset through drug discovery, preclinical research and beyond.
Unlike many contract research organisations (CROs) that rely on standardised, off-the-shelf assays, our scientific solutions include custom assays and models, built from first principles. Our combination of integrated teams and unique technologies allows RxCelerate to develop the optimal drug discovery strategy to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional CRO approaches.